We investigated the possibility that cathepsin D, an estrogen-induced lysosomal protease, might have value as a prognostic factor in breast cancer by studying frozen tissue specimens from 397 patients. We measured the 34-kd mature form of the enzyme by Western blot assay and densitometry. Among 199 patients with node-negative disease, but not among 198 with node-positive disease, high levels of cathepsin D proved to be a significant predictor of reduced disease-free survival (median follow-up, 64 months), either as a continuous variable (log cathepsin D; P = 0.018) or as a dichotomous variable with an optimized cutoff point (P = 0.0001). Results were similar for overall survival (P = 0.009 and 0.0001, respectively). Relating the level of cathepsin D to other prognostic factors in the patients with node-negative disease, we found an association with aneuploidy but none with estrogen or progesterone receptors, tumor size, or the age of the patient. In multivariate analyses, a high level of cathepsin D was the most important independent factor in predicting shorter disease-free and overall survival in patients with node-negative disease. As compared with the risk in women with low levels of cathepsin D, the relative risk of tumor recurrence was 2.6 (95 percent confidence interval, 1.6 to 4.4) and the relative risk of death was 3.9 (95 percent confidence interval, 2.1 to 7.3) among those with high levels of cathepsin D. For disease-free survival, cathepsin D status was predictive of outcome primarily among those with aneuploid tumors; the actuarial five-year recurrence rates of aneuploid tumors were 60 percent among women with high levels of cathepsin D and 29 percent among those with low levels, as compared with 22 percent for all diploid tumors. We conclude that cathepsin D may be an independent predictor of early recurrence and death in node-negative breast cancer.
Source Information
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7884.
This article has been cited by other articles:
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., Nakajima, Y.
(2007). Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer. Clin. Cancer Res.
13: 2151-2157
[Abstract][Full Text]
Tokuhara, T., Hattori, N., Ishida, H., Hirai, T., Higashiyama, M., Kodama, K., Miyake, M.
(2006). Clinical Significance of Aminopeptidase N in Non-Small Cell Lung Cancer.. Clin. Cancer Res.
12: 3971-3978
[Abstract][Full Text]
Egberts, F., Heinrich, M., Jensen, J.-M., Winoto-Morbach, S., Pfeiffer, S., Wickel, M., Schunck, M., Steude, J., Saftig, P., Proksch, E., Schutze, S.
(2004). Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation. J. Cell Sci.
117: 2295-2307
[Abstract][Full Text]
Iwasaki, A., Kuwahara, M., Yoshinaga, Y., Shirakusa, T.
(2004). Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur. J. Cardiothorac. Surg.
25: 443-448
[Abstract][Full Text]
Tokuhara, T., Hasegawa, H., Hattori, N., Ishida, H., Taki, T., Tachibana, S., Sasaki, S., Miyake, M.
(2001). Clinical Significance of CD151 Gene Expression in Non-Small Cell Lung Cancer. Clin. Cancer Res.
7: 4109-4114
[Abstract][Full Text]
Harbeck, N., Alt, U., Berger, U., Kruger, A., Thomssen, C., Janicke, F., Hofler, H., Kates, R. E., Schmitt, M.
(2001). Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy. Clin. Cancer Res.
7: 2757-2764
[Abstract][Full Text]
Martinez, J. M., Prieto, I., Ramirez, M. J., Cueva, C., Alba, F., Ramirez, M.
(1999). Aminopeptidase Activities in Breast Cancer Tissue. Clin. Chem.
45: 1797-1802
[Abstract][Full Text]
Yamashita, J.-i., Ogawa, M., Abe, M., Nishida, M.
(1999). Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase Concentrations Differ in Small Cell and Non-small Cell Lung Cancer. Chest
116: 206-211
[Abstract][Full Text]
Journet, A, Chapel, A, Jehan, S, Adessi, C, Freeze, H, Klein, G, Garin, J
(1999). Characterization of Dictyostelium discoideum cathepsin D. J. Cell Sci.
112: 3833-3843
[Abstract]
Utsumi, T., Yoshimura, N., Takeuchi, S., Ando, J., Maruta, M., Maeda, K., Harada, N.
(1999). Steroid Sulfatase Expression Is an Independent Predictor of Recurrence in Human Breast Cancer. Cancer Res.
59: 377-381
[Abstract][Full Text]
Duffy, M. J., Duggan, C., Mulcahy, H. E., McDermott, E. W., O'Higgins, N. J.
(1998). Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin. Chem.
44: 1177-1183
[Abstract][Full Text]
Diamandis, E. P., Nadkarni, S., Bhaumik, B., Abdelrahman, A., Melegos, D. N., Borchert, G., Black, M. H., Alonso, M., Salas, A., de los Toyos, J. R., Sampedro, A., Lopez-Otin, C.
(1997). Immunofluorometric assay of pepsinogen C and preliminary clinical applications. Clin. Chem.
43: 1365-1371
[Abstract][Full Text]
Hradek, D. I., Kessel, B., Husseinzadeh, N., Moulton, B. C.
(1994). Cathepsin D Activity in Human Ovarian Tissues and Ovarian Carcinoma. Reproductive Sciences
1: 173-177
[Abstract]
(1990). A NEW PROGNOSTIC MARKER FOR BREAST CANCER. JWatch General
1990: 3-3
[Full Text]
Previous
